Skip to main content
  • New Late-Breaking Data Reinforce the Benefits of Abbott's TriClip™ Device for People With Tricuspid Valve Disease

    • Data presented at EuroPCR 2023 build on prior study results demonstrating TriClip is a safe and effective therapy to treat leaky tricuspid valves
    • Findings from the largest real-world dataset for tricuspid repair show device reduces tricuspid regurgitation and improves quality of life 

    ABBOTT PARK, Ill., May 17, 2023 — Abbott today announced late-breaking data that add to the body of clinical evidence supporting the benefits of the TriClip™ transcatheter edge-to-edge repair (TEER) system in treating patients with leaky tricuspid valves. Abbott's TriClip device is a first-of-its kind, minimally invasive device designed specifically for tricuspid heart valve repair.

    The results were presented at EuroPCR, the annual meeting of the European Association of the Percutaneous Cardiovascular Interventions, held in Paris from May 16-19, 2023. 

    30-Day Outcomes From the TriClip bRIGHT Study

    The results of the bRIGHT study, the largest real-world dataset for transcatheter tricuspid valve repair, support the safety and effectiveness of the TriClip system in patients with tricuspid regurgitation (TR). Outcomes from 511 patients in 26 sites across Europe for this prospective, multi-center, single-arm post-market study were presented for the first time at EuroPCR 2023.

    Key findings through 30 days include:

    • Significant TR reduction. Repair with the TriClip system resulted in reduction of TR grade to moderate or less for 77% of the patients.
    • Significant clinical and quality of life improvements. 79% of participants achieved New York Heart Association (NYHA) Functional Class I/II (meaning they reached a point of slight or no limitation of physical activity), a nearly 60% improvement from the baseline proportion of 20%. In addition, more than half (56%) of patients reported a 15-point improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score (a self-assessment of symptoms, physical and social limitations, and quality of life), representing a substantial improvement in quality of life and health status.
    • A strong safety profile. Only 2.5% of patients who received the device experienced a major adverse event, a composite of cardiovascular death, heart attack, stroke, new onset of kidney failure and surgery for device-related adverse events.

    "Many patients currently undergoing tricuspid TEER are at an advanced stage of the TR disease and experience severe symptoms, impacting their overall health and well-being," said Philipp Lurz, M.D., Ph.D., professor and deputy head of cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. "Building strong clinical evidence around the value of a procedure like tricuspid valve repair is critical, and the real-world outcomes of the bRIGHT study reinforce the safety and effectiveness of TriClip in reducing TR and improving quality of life."

    "Just as we lead the way for treating mitral regurgitation with our MitraClip device, we're excited about the opportunity to continue our track record of innovation to treat tricuspid regurgitation with our TriClip therapy," said Michael Dale, senior vice president of Abbott's structural heart business. "TriClip has already helped thousands of people in Europe since its introduction in 2020. As we work to make TriClip accessible to more people around the world, the latest data presented at EuroPCR are further proof that the therapy helps patients who have limited treatment options get back to living fuller, healthier lives."

    TriClip is approved for use in more than 50 countries, including in Europe and Canada, and is an investigational device in the U.S.

    About Abbott:

    Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.

    Connect with us at, on LinkedIn at, on Facebook at and on Twitter @AbbottNews.

    Abbott Media:

    Cynthia Kong, (669) 400-6879

    Abbott Financial:

    Mike Comilla, (224) 668-1872


    Read original article here:

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details